US20060003343A1 - Primer and probe design for efficient amplification and detection of HCV 3' non-translating region - Google Patents

Primer and probe design for efficient amplification and detection of HCV 3' non-translating region Download PDF

Info

Publication number
US20060003343A1
US20060003343A1 US11/040,417 US4041705A US2006003343A1 US 20060003343 A1 US20060003343 A1 US 20060003343A1 US 4041705 A US4041705 A US 4041705A US 2006003343 A1 US2006003343 A1 US 2006003343A1
Authority
US
United States
Prior art keywords
seq
nucleic acid
primer
hcv
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/040,417
Other languages
English (en)
Inventor
Hwa-Tang Wang
Brian Washburn
Prakash Purohit
Lawrence Burg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux Inc
Original Assignee
Biomerieux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Inc filed Critical Biomerieux Inc
Priority to US11/040,417 priority Critical patent/US20060003343A1/en
Assigned to BIOMERIEUX, INC. reassignment BIOMERIEUX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PUROHIT, PRAKASH, WANG, HWA-TANG THOMAS, BURG, LAWRENCE, WASHBURN, BRIAN
Publication of US20060003343A1 publication Critical patent/US20060003343A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Definitions

  • the present invention relates to oligonucleotides that bind to the 3′ non-translating region (3′NTR) of Hepatitis C Virus (HCV), useful for the detection and/or quantification of HCV. Also provided are methods of nucleic acid assays useful in the detection, capture and amplification of HCV utilizing the 3′NTR as the target region.
  • 3′NTR 3′ non-translating region
  • HCV Hepatitis C Virus
  • enzymatic amplification of nucleic acid sequences will enhance the ability to detect a desired nucleic acid sequence.
  • the currently known amplification schemes can be broadly grouped into two classes based on whether the enzymatic amplification reactions are driven by continuous cycling of the temperature between the denaturation temperature, the primer annealing temperature, and the amplicon (product of enzymatic amplification of nucleic acid) synthesis temperature, or whether the temperature is kept constant throughout the enzymatic amplification process (isothermal amplification).
  • Typical cycling nucleic acid amplification technologies are polymerase chain reaction (PCR), and ligase chain reaction (LCR).
  • reactions which are isothermal include: transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), and strand displacement amplification (SDA).
  • TMA transcription-mediated amplification
  • NASBA nucleic acid sequence-based amplification
  • SDA strand displacement amplification
  • U.S. Pat. Nos. 4,683,195 (Mullis); 4,965,188 (Mullis); and 4,683,202 (Mullis) describe a polymerase chain reaction (PCR) utilizes DNA polymerase, complementary primer molecules and repeated cycles of thermal reactions to exponentially replicate target nucleic acid molecules.
  • Isothermal target amplification methods include transcription-based amplification methods, in which an RNA polymerase promoter sequence is incorporated into primer extension products at an early stage of the amplification (WO 89/01050), and further target sequence, or target complementary sequence, is amplified by transcription steps and digestion of an RNA strand in a DNA/RNA hybrid intermediate product. See, for example, U.S. Pat. Nos. 5,169,766 and 4,786,600.
  • TMA transcription mediated amplification
  • SR self-sustained sequence replication
  • NASBA Nucleic Acid Sequence Based Amplification
  • Other approaches include Q.beta. replicase, strand displacement assay (SDA), transcription mediated iso CR cycling probe technology, nucleic acid sequence-based amplification (NASBA) and cascade rolling circle amplification (CRCA).
  • Additional U.S. Patent documents which describe nucleic acid amplification include U.S. Pat. Nos. 4,876,187; 5,030,557; 5,399,491; 5,485,184; 5,554,517; 5,437,990; 5,399,491 and 5,554,516.
  • nucleic acids are often labeled for various detection purposes.
  • methods described in U.S. Pat. Nos. 4,486,539 (Kourlisky); 4,411,955 (Ward); 4,882,269 (Schneider) and 4,213,893 (Carrico) illustrate preparation of labeled detection probes for detecting specific nucleic acid sequences.
  • the target nucleic acid can be immobilized by target-capture means, either directly or indirectly, using a “capture probe” bound to a substrate, such as a magnetic bead.
  • HCV has been classified as the sole member of a distinct genus called Hepacivirus in the family
  • Flaviviridae HCV is an enveloped particle harboring a plus-strand RNA with a length of approximately 9600 nucleotides.
  • the genome carries a single long open reading frame (ORF) encoding a polyprotein that is proteolytically cleaved into a set of distinct products.
  • An approximately 340 nucleotide-long 5′ non-translated region (NTR) functions as an internal ribosome entry site (IRES) for translation of the HCV ORF (Tsukiyama-Kohara et al., J. Virol. 66: 1476-1483 (1992); Wang et al., J. Virol.
  • the HCV 3′nontranslated region has been found to include four elements (positive sense, 5′ to 3′): (i) a short sequence with significant variability among genotypes, (ii) a homopolymeric poly(U) tract, (iii) a polypyrimidine stretch consisting of mainly U with interspersed C residues, (iv) a novel sequence of 98 bases (the X-region). This latter nucleotide sequence is not present in human genomic DNA and is highly conserved among HCV genotypes (Kolykhalov et al. (1996); Pavio and Lai, J. Biosci. 28(3): 287-304 (2003)).
  • HCV infections persist, leading in about 50% of all cases to chronic hepatitis, which can develop into chronic active hepatitis, liver cirrhosis and hepatocellular carcinoma. Furthermore, HCV is distributed worldwide, with the number of infected individuals being estimated to be ⁇ 170 million. (Bartenschlager and Lohmann (2000). Thus, a definitive diagnostic test is needed to identify infected individuals. Furthermore, HCV genotyping in patients is essential for diagnostic and epidemiological studies, as well as in studies of the natural history and treatment of HCV.
  • HCV RNA Detection of HCV RNA is the diagnostic test utilized for acute and chronic HCV infection. However, it is often complicated by the low levels of HCV replication or small numbers of infected cells in hepatitis C patients (Shi and Lai (2000)). Most qualitative and quantitative diagnostic tests are RTPCR aiming at the 5′-UTR, the most conserved region of the HCV genome. However, the sensitivity of this method has been reported to be accompanied by problems of false priming, presumably in areas of RNA secondary structure (Shi and Lai (2000)). This has been partially addressed by the use of tagged primers or a thermostable reverse transcriptase (Lanford, Virology 202: 606-614 (1994)). Since the core and NS5B genes are relatively conserved and do not contain extensive secondary structures, they have also been employed in various detection methods.
  • the X region of the 3′-UTR is another highly conserved region in the HCV genome, but it is highly structured.
  • the 3′ HCV NTR is considered a difficult amplification target for at least two reasons: it forms highly stable secondary structures; and the NTR is very small. It has not been used in the detection of HCV RNA due, at least in part, to its lack of practical advantages over the well-established tests based on the 5′-UTR sequence (Shi and Lai (2000)).
  • primer and probe designs that provide more useful and reliable results in detection of the presence of HCV.
  • primers and probes that are aimed at overcoming the complications of 3′ NTR secondary structure, type specificity and palindrome sequences that could affect the hybridization process and providing improved means for the detection, capture, and/or amplification of HCV nucleic acids.
  • the present invention provides oligonucleotides that address these needs to help solve such issues.
  • the present invention provides an isolated Hepatitis C virus-derived nucleic acid comprising a nucleotide sequence selected from the group consisting of specific nucleic acid sequences corresponding to a portion of the 3′NTR of HCV.
  • oligonucleotides are useful in detecting the presence of HCV nucleic acids.
  • the present invention provides an isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24; SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO:32, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO:43.
  • the present invention further provides an isolated nucleic acid comprising (a) a tag oligonucleotide having a 5′ end and a 3′ end, and (b) a primer nucleic acid having a 5′ end and a 3′ end and comprising a nucleotide sequence corresponding to a portion of the 3′NTR of HCV, wherein the tag oligonucleotide consists of about 18 to about 23 randomly selected nucleotides heterologous to HCV and is linked at its 3′ end to the 5′ end of the primer nucleic acid.
  • the present invention further provides an isolated nucleic acid comprising (a) a tag oligonucleotide having a 5′ end and a 3′ end, and (b) a primer nucleic acid having a 5′ end and a 3′ end and comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO: 8, wherein the tag oligonucleotide consists of about 18 to about 23 randomly selected nucleotides heterologous to HCV and is linked at its 3′ end to the 5′ end of the primer nucleic acid.
  • the present invention additionally provides a method of assaying for the presence of HCV in a nucleic acid sample comprising (a) amplifying a selected HCV nucleic acid to form an HCV amplification product, utilizing as a primer of amplification a nucleic acid comprising a nucleotide sequence selected from the group consisting of specific nucleic acid sequences corresponding to a portion of the 3′NTR of HCV, and (b) detecting the presence of amplified product.
  • the present invention additionally provides a method of assaying for the presence of HCV in a nucleic acid sample comprising (a) amplifying a selected HCV nucleic acid to form an HCV amplification product, utilizing as a primer of amplification a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24; SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO:32, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO:43, and (b) detecting the presence of amplified product.
  • the instant invention further provides a method of quantifying the amount of HCV nucleic acid in a sample comprising (a) amplifying selected HCV nucleic acid to form an HCV amplification product, utilizing as a primer of amplification a nucleic acid comprising a nucleotide sequence selected from the group consisting of specific nucleic acid sequences corresponding to a portion of the 3′NTR of HCV, and (b) quantifying the amount of amplified product.
  • the instant invention further specifically provides a method of quantifying the amount of HCV nucleic acid in a sample comprising (a) amplifying selected HCV nucleic acid to form an HCV amplification product, utilizing as a primer of amplification a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24; SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO:32, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO:43, and (b) quantifying the amount of amplified product.
  • a method of assaying for the presence of HCV in a nucleic acid sample comprising (a) amplifying a target nucleic acid comprising a selected portion of the 3′NTR of HCV and (b) detecting the presence of amplified product utilizing a probe comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22; SEQ ID NO:19, SEQ ID NO: 24, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 44.
  • FIG. 1 provides a schematic of the 3′ NTR of HCV (98 sequences), showing the general region of hybridization of P1 primers, P2 primers and detection probes.
  • the 3′ HCV NTR is considered a difficult amplification target for at least two reasons. First, it forms highly stable secondary structures. The intramolecular pairing (including potential double-stranded (stem) and palindrome regions) is expected to cause difficulties for primer binding, primer extension, and probe binding. Secondly, the NTR is very small (98 nt), resulting in unusually limited primer and probe choices, and an amplicon of sub-optimal length (amplicons are ideally >100 nt). The inability to reduce secondary structure by raising the temperature (as in PCR) makes it particularly problematic for isothermal amplification methods such as TMA and NASBA. The present invention provides primers and probes that help overcome these challenges.
  • the 3′ NTR of Hepatitis C virus has the following sequence: Genotype 1: GGUGGCUCCAUCUUAGCCCUAGUCACGGCUAGCUGUGAAAGGUCCGUGAGCCGCAUGACUG (SEQ ID NO: 25) CAGAGAGUGCUGAUACUGGCCUCUCUGCAGAUCAUGU Genotype 2: GGUGGCUCCAUCUUAGCCCUAGUCACGGCUAGCUGUGAAAGGUCCGUGAGCCGCAUGACUG (SEQ ID NO: 26) CAGAGAGUGC C G UA ACUGG U CUCUCUGCAGAUCAUGU
  • Genotype 1 The most common sequence differences between Genotype 1 and Genotype 2 are indicated by underlining. Although the region is highly conserved, additional nucleotide differences may also be present in the individual isolates.
  • the present invention provides oligonucleotides, derived from the 3′ NTR of Hepatitis C virus, found to be particularly useful in assays to detect the presence, or quantify the amount of, HCV nucleic acids in selected samples.
  • nucleic acid sequences may have descriptors that include an “nt” range of numbers. Such descriptor indicates where, within the 98 nucleotides of the 3′HCV NTR, the sequence corresponds, the first of the 98 nucleotides, reading in a 5′-3′ direction along the viral genome, having the number “1”.
  • the following oligonucleotide “1206 (nt5-24)” indicates that the sequence of the oligonucleotide named 1206 has a nucleic acid sequence that corresponds to nucleotides 5-24 of the 3′NTR.
  • references to sequences that include thymidine can be readily adapted to utilize uridine in substitution for thymidine, where useful for the particular assay.
  • nucleotides may be modified by addition of chemical groups, or substitution of individual residues by analogues (e.g., 2′-O-methoxy versions).
  • modified nucleotides are known in the art; some examples include hydroxymethyl nucleotides, methylated nucleotides, fluorinated nucleotides, alpha this phosphate nucleotides, amine-modified nucleotides, methoxy nucleotides, carboxymethyl nucleotides, thio nucleotides, inosine, dihydrouridine, psuedouridine, wybutosine, queuosine, C7dGTP. Additional modified nucleotides are found in U.S. Pat. Nos 5,405,950 and 5,633,364 (both, Mock and Lovern).
  • the invention particularly provides an isolated Hepatitis C virus-derived nucleic acid comprising a nucleotide sequence selected from the group consisting of specific nucleic acid sequences corresponding to a portion of the 3′NTR of HCV.
  • the present invention provides an isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO:32.
  • nucleic acid consisting essentially of a nucleotide sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO:32.
  • the nucleotide sequence of the oligonucleotide thus can further have from one to four mismatches from the recited nucleotide sequence, wherein the oligonucleotide hybridizes, under NASBA hybridization conditions, to the 3′NTR of HCV.
  • NASBA conditions are known in the art and can include, for example, parameters creating stringency provided by about 41° C. and about 70 mM KCl (see. e.g., U.S. Pat. Nos. 5,466,586; 5,409,818; 5,554,517; 6,063,603; and 5,130,238; Deiman B, van Aarle P, Sillekens P. Characteristics and applications of nucleic acid sequence-based amplification (NASBA).
  • Such sequences can have from one to four mismatches from HCV 3′′ NTR genomic sequence, wherein the oligonucleotide hybridizes, under NASBA hybridization conditions, to the 3′NTR of HCV. Examples of mismatches are exemplified herein.
  • Oligonucleotides of the present invention can be utilized, for example, as primers and/or as probes for the detection of HCV nucleic acids in a sample.
  • a particular oligonucleotide may be exemplified in use as a particular type (e.g. P1-type (linked to a sequence that provides a promoter region when in double-stranded form) or P2 type (used alone or linked to a tag oligonucleotide)) primer or as a probe; however, such use should not limit the use(s) for which the oligonucleotide may be useful.
  • a primer exemplified as a P1 primer may be useful as a P2-type primer.
  • an oligonucleotide exemplified for use as a probe may be useful as the base HCV-hybridizing sequence for other styles of probes (e.g., having different labels or capture oligonucleotides or other structures for functioning of that probe type).
  • the present invention provides amplicon length modulation through the use of the attachment of non-related sequence at the 5′ end of primers.
  • non-related sequences are particularly useful for non-promoter-linked primers, such as P2 primers herein.
  • the present invention further provides an isolated nucleic acid comprising (a) a tag oligonucleotide having a 5′ end and a 3′ end, and (b) a primer nucleic acid having a 5′ end and a 3′ end and comprising a nucleotide sequence corresponding to a portion of the 3′NTR of HCV, wherein the tag oligonucleotide consists of about 18 to about 23 randomly selected nucleotides heterologous to HCV and is linked at its 3′ end to the 5′ end of the primer nucleic acid.
  • the present invention further provides an isolated nucleic acid comprising (a) a tag oligonucleotide having a 5′ end and a 3′ end, and (b) a primer nucleic acid having a 5′ end and a 3′ end and comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO: 8, wherein the tag oligonucleotide consists of about 18 to about 23 randomly selected nucleotides heterologous to HCV and is linked at its 3′ end to the 5′ end of the primer nucleic acid.
  • the tag oligonucleotide (or “tail”) is a sequence heterologous to the target nucleic acid, and, more preferably, heterologous to any region of HCV.
  • the tag oligonucleotide can comprise any selected heterologous sequence of about 18-23 nucleotides.
  • An approximately 20-mer oligonucleotide “tail” can readily be designed by one skilled in the art, given these teachings, to create additional detection tails useful with (non-promoter-carrying) primers to increase detectable amplicons from an amplification reaction.
  • the tail is preferably comprised of sequences heterologous to the target nucleic acid.
  • the oligonucleotide tail can be from about 18 to about 23 nucleotides in length, is preferably about 19-22 nucleotide in length, more preferably about 20-21 nucleotides in length, and most preferably 20 nucleotides in length.
  • ECL electrohydriluminescence
  • the tag oligonucleotide comprises an ECL tag; more particularly, the nucleotide sequence set forth in SEQ ID NO: 9.
  • the oligonucleotide comprises a tag oligonucleotide linked at its 3′ end to the 5′ end of a primer having a nucleic acid sequence set forth in SEQ ID NO: 8.
  • the present invention provides a preferred isolated nucleic acid comprising a nucleotide sequence set forth in SEQ ID NO: 37, which consists of an ECL tag linked at its 3′ end to the 5′ end of the primer (herein referred to as “1259”) having a nucleotide sequence set forth in SEQ ID NO:8.
  • the present invention further provides an isolated nucleic acid comprising (a) a promoter oligonucleotide that, when in double-stranded form, can function as a T7 promoter, and (b) a primer nucleic acid having a 5′ end and a 3′ end and comprising a nucleotide sequence comprising a nucleotide sequence corresponding to a portion of the 3′NTR of HCV.
  • the present invention provides an isolated nucleic acid comprising (a) a promoter oligonucleotide that, when in double-stranded form, can function as a T7 promoter, and (b) a primer nucleic acid having a 5′ end and a 3′ end and comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, wherein the promoter oligonucleotide is linked at its 3′ end to the 5′ end of the primer nucleic acid.
  • the nucleic acid sequence of the T7 promoter is well-known to persons skilled in the art, and though a particular sequence is exemplified herein, functional equivalents having slight variations may be designed.
  • the sequence of the T7 promoter is that set forth in SEQ ID NO:38.
  • a further example is provided by SEQ ID NO: 23.
  • An oligonucleotide having T7 promoter sequences is useful as a primer, and, when utilized as such, is herein referred to as a “P1 primer,” P1-type primer,” “promoter-oligonucleotide,” or simply as “P1.”
  • P1 primer a transcription-based amplification reaction
  • these T7 promoter sequences have a function in the amplification reaction, priming the transcription of RNA from the target template, in this case, HCV.
  • the nucleotide sequences of primers exemplified herein as of the “P1” type are typically listed without the T7 promoter sequences, but in the experiments, such T7 promoter sequences are present.
  • a method of assaying for the presence of HCV in a nucleic acid sample comprising (a) amplifying a target nucleic acid comprising a selected portion of the 3′NTR of HCV and (b) detecting the presence of amplified product utilizing a probe comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22; SEQ ID NO:19, SEQ ID NO: 24, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 44.
  • any useful HCV primer(s) can be utilized; examples are provided herein.
  • Assay conditions are known to those of skill in the are and exemplified herein.
  • Oligonucleotides of the present invention can have various uses. They can, for example, be utilized as probes in capture and detection reactions, and as primers and/or probes in various amplification reactions.
  • primers and probes utilized for 3′ HCV amplification and exemplified by TMA-and NASBA. Both of these methods use isothermal amplification to produce RNA amplicons through the combined use of reverse transcriptase and T7 polymerase. Because of these similarities, the primers and probes are expected to share some performance similarity in the two systems, and experiments (see Examples) support this.
  • the present invention additionally provides a method of assaying for the presence of HCV in a nucleic acid sample comprising (a) amplifying a selected HCV nucleic acid to form an HCV amplification product, utilizing as a primer of amplification a nucleic acid comprising a nucleotide sequence selected from the group consisting of specific nucleic acid sequences corresponding to a portion of the 3′NTR of HCV, and (b) detecting the presence of amplified product.
  • invention provides a method of assaying for the presence of HCV in a nucleic acid sample comprising (a) amplifying a selected HCV nucleic acid to form an HCV amplification product, utilizing as a primer of amplification a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, and (b) detecting the presence of amplified product.
  • Nucleic acids can be labeled for use in detection.
  • detectable labels have been conjugated, directly or indirectly through linker arms on either the base, sugar or phosphate moiety of one or more specific oligonucleotides (see, e.g., U.S. Pat. Nos. 4,486,539 (Kourlisky); 4,411,955 (Ward); 4,882,269 (Schneider) and 4,213,893 (Carrico)).
  • Labels known in the art include fluorochromes, radioisotopes, dyes, enzymes such as alkaline phosphatase, and luminescent or chemiluminescent molecules.
  • Detectably labeled probes may, for example, be used to bind to amplified nucleic acid reaction products or amplicons during or after an amplification reaction.
  • Particularly useful probes are those that can detect the target under the preferred conditions for the assay and type of probe utilized; typical hybridization conditions can be stringent hybridization conditions such as taught by Sambrook, et al.
  • This invention involves the primer and probe designs for efficient capture, amplification and detection of HCV 3′ end 98-base non-translated region.
  • the primer designs can be applied for TMA, NASBA, SDA, PCR and other amplification methods.
  • the present oligonucleotides are useful in the present detection and quantification assays. Amplification can be performed by thermocycling methods or isothermal methods.
  • the present oligonucleotides are particularly useful, and preferably used in, transcription based amplification methods, for example, NASBA and TMA. Transcription based amplification methods often utilize single stranded RNA as the input material, although single or double stranded DNA can likewise be used as input material.
  • a pair of oligonucleotides that is conveniently used with the methods can include (1) a first oligonucleotide (often referred to as a “promoter-oligonucleotide”, or “P1” primer) that is capable of hybridizing to the 3-end of the target sequence, which oligonucleotide has the sequence of a promoter (preferably the T7 promoter) attached to its 5′ end (the hybridizing part of this oligonucleotide has the opposite polarity as the plus RNA used as input material); and (2) a second oligonucleotide (“primer”) which comprises the 3′ end of the target sequence (this oligonucleotide has the same polarity as the plus RNA).
  • a promoter preferably the T7 promoter
  • the first primer can be an oligonucleotide provided here and can lack a T7 promoter sequence.
  • the present olgionucleotides can provide probes for detection of amplicons.
  • the probe designs provided herein are for target capture (sample preparation), amplicon capture, and amplicon detection, which methods are know in the art. Probe designs for different detection methods: HPA, TAQman, molecular Beacons and Sandwich hybridization have also been discovered. These designs demonstrate the efficient capture and detection by hybridization to amplicons
  • the primers utilized may be referred to as P1 primers or P2 primers.
  • This terminology simply indicates that, within a NASBA or TMA reaction in these examples, the P1 primer is the primer having a T7 promoter sequence attached to its 5′ end (promoter primer); the P2 primer does not. It is not limiting terminology.
  • RNA target was then denatured at 65° C., then amplified by TMA (standard conditions; McDonough et al., Nucleic acid amplification technologies 1998:113-123 BioTechniques Books Natick, Mass., Lee H Morse S Olsvik ⁇ eds.) at 42° C. with primers 1259 (SEQ ID NO: 8) and 1236 (SEQ ID NO: 11).
  • TMA standard conditions; McDonough et al., Nucleic acid amplification technologies 1998:113-123 BioTechniques Books Natick, Mass., Lee H Morse S Olsvik ⁇ eds.
  • primers 1259 SEQ ID NO: 8
  • 1236 SEQ ID NO: 11
  • the RAR-resuspended purified target was then added to VIDAS Probe strips (containing all additional reagents required for amplification and detection, such as enzymes, probes, wash solutions, and detection substrate).
  • the amplification was carried out in bioMerieux AmpStations, and then transferred to VIDAS instruments, which carried out sequence-specific capture of the amplicons, washing, and detection with a fluorescent-conjugate probe specific for the 3′ end.
  • the SPR Probe 1247 (SEQ ID NO: 22) captures the amplicon on the VIDAS SPR.
  • the AKP Probe (1246) (SEQ ID NO: 21) was conjugated to alkaline phosphatase and binds to the purified amplicon, providing detection via fluorescent AKP substrate.
  • the 1236/1259 (P1/P2) primer pair which performed optimally in the TMA assay, was analyzed for use in NASBA amplification. Additional primers providing a larger predicted amplicon were also tested, for example primer P1: 1211 (nt83-64) (SEQ ID NO: 10) and primer P2:VP1206 (nt5-24) (SEQ ID NO: 1).
  • probes were designed to bind to a region corresponding to a combination of the VIDAS Probe amplicon capture probe and amplicon detection probe sites from the previous example. Probes were based upon an HCV base sequence of either TGAAAGGTCCGTGAGCCGC (nt 36-54) (SEQ ID NO: 43) or TGTGAAAGGTCCGTGAGCCGC (nt34-54) (SEQ ID NO: 44). These probes were tested as capture probes (EG6, EG7) in the ECL assay (see below) or as the amplicon-binding (“loop”) portion of molecular beacons (MB140 (EG18) (SEQ ID NO: 24); MB102 (Q1) (SEQ ID NO: 41)
  • ECL electrochemical chromescence
  • NASBA bioMerieux, Inc., Durham, N.C.
  • ECL tail ECL detection tag
  • SEQ ID NO: 9 ECL detection tag
  • HCV dilution P2 10x 100x 1000x neg ECL-tagged 1259 3.2E+07 4.4E+06 2.0E+05 3.1E+03 1 1259 2.1E+06 6.9E+05 2.1E+04 1.3E+01 1
  • HCV amplicon is very small (70 nt without tag, increased to 90 with tag), and small amplicons may be relatively inefficient in NASBA.
  • P1 (promoter) primers was tested for function in NASBA, as listed in Table 7. This set of primers spans, and moves in the 3′ direction in one-nucleotide increments, from the position of primer 1236 to (at the 3′ end of the final primer P1.89) the position 3 bases from the probe-binding site. Of this set of primers, the best functioning (comparably to primer 1236) to produce detectable signal were P1.63, P1.82, P1.83, P1.84, and P1.85. The P2 used for these tests was EG4 and probe was EG18 (fluorescence values were normalized).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
US11/040,417 2004-01-23 2005-01-21 Primer and probe design for efficient amplification and detection of HCV 3' non-translating region Abandoned US20060003343A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/040,417 US20060003343A1 (en) 2004-01-23 2005-01-21 Primer and probe design for efficient amplification and detection of HCV 3' non-translating region

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53881604P 2004-01-23 2004-01-23
US53881504P 2004-01-23 2004-01-23
US53881404P 2004-01-23 2004-01-23
US11/040,417 US20060003343A1 (en) 2004-01-23 2005-01-21 Primer and probe design for efficient amplification and detection of HCV 3' non-translating region

Publications (1)

Publication Number Publication Date
US20060003343A1 true US20060003343A1 (en) 2006-01-05

Family

ID=34812082

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/040,417 Abandoned US20060003343A1 (en) 2004-01-23 2005-01-21 Primer and probe design for efficient amplification and detection of HCV 3' non-translating region
US11/040,371 Expired - Lifetime US7364854B2 (en) 2004-01-23 2005-01-21 Nucleotide mixture for improved nucleic acid amplification performance
US12/069,606 Expired - Fee Related US7670779B2 (en) 2004-01-23 2008-02-11 Nucleotide mixture for improved nucleic acid amplification performance

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/040,371 Expired - Lifetime US7364854B2 (en) 2004-01-23 2005-01-21 Nucleotide mixture for improved nucleic acid amplification performance
US12/069,606 Expired - Fee Related US7670779B2 (en) 2004-01-23 2008-02-11 Nucleotide mixture for improved nucleic acid amplification performance

Country Status (6)

Country Link
US (3) US20060003343A1 (enExample)
EP (3) EP1721015B1 (enExample)
JP (2) JP4866248B2 (enExample)
AT (3) ATE417938T1 (enExample)
DE (3) DE602005023586D1 (enExample)
WO (2) WO2005071117A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134374A1 (en) * 2007-04-27 2008-11-06 Eragen Biosciences, Inc. Materials and methods for detection of hepatitis c virus
JP2009284896A (ja) * 2007-07-26 2009-12-10 Fujifilm Corp 核酸増幅方法
EP2058406A3 (en) * 2007-11-06 2009-10-28 Fujifilm Corporation RNA detection method
RU2011132045A (ru) * 2008-12-31 2013-02-10 Эбботт Лэборетриз Праймеры и зонды для детектирования вируса гепатита с

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032511A (en) * 1987-03-31 1991-07-16 Mitsubishi Kasei Corporation DNA fragments coding for antigens specific to non-A non-B hepatitis, expression vectors containing said DNA fragments, transformants and process for producing said antigens
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5837463A (en) * 1919-10-17 1998-11-17 Rational Drug Design Laboratories Nucleic acid of C type hepatitis virus derivation and process for detection virus using said nucleic acid
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US6074816A (en) * 1987-11-18 2000-06-13 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3164463D1 (en) * 1980-11-12 1984-08-02 Mitsubishi Chem Ind Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives
US5087565A (en) * 1984-07-02 1992-02-11 Du Pont Merck Pharmaceutical Company Synthetic process for preparation of 32 P-labeled nucleotides
JPH0723393B2 (ja) * 1985-05-15 1995-03-15 アモコ・コーポレーション シチジン同族体
US4876187A (en) 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
FI891436L (fi) 1987-07-31 1989-03-23 Univ Leland Stanford Junior Selektivt flerfaldigande av targetpolynukleotidsekvenser.
US5030557A (en) 1987-11-24 1991-07-09 Ml Technology Venture Means and method for enhancing nucleic acid hybridization
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
CA2025536C (en) 1989-09-18 1995-04-18 Hiroshi Nakagomi Ink jet recording head and ink jet recording apparatus having same
WO1991012342A1 (en) * 1990-02-16 1991-08-22 F. Hoffmann-La Roche Ag Improvements in the specificity and convenience of the polymerase chain reaction
CA2135073C (en) 1992-05-06 2002-11-19 Daniel L. Kacian Nucleic acid sequence amplification method, composition and kit
US5648232A (en) * 1993-01-21 1997-07-15 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Microbiological best method and reagents
CA2184270C (en) * 1994-03-10 1999-08-17 Daniel Louis Kacian Method for suppressing inhibition of enzyme-mediated reactions by ionic detergents
DE19612779A1 (de) 1996-03-29 1997-10-02 Boehringer Mannheim Gmbh Verfahren zur spezifischen Vervielfältigung von langen Nukleinsäuren durch PCR
EP2264045B1 (en) * 1996-08-14 2015-10-21 Life Technologies Corporation Stable compositions for nucleic acid amplification and sequencing
DE19647055A1 (de) * 1996-11-14 1998-05-20 Boehringer Mannheim Gmbh Stabilisierte wässrige Nukleosidtriphosphat-Lösungen
WO1998044161A1 (en) * 1997-04-03 1998-10-08 Life Technologies, Inc. Compositions and methods for reverse transcriptase-polymerase chain reaction (rt-pcr)
ZA989950B (en) * 1997-11-17 1999-05-04 Akzo Nobel Nv Transcription based amplification of double stranded DNA targets
JP2002512791A (ja) * 1998-04-27 2002-05-08 リボザイム・ファーマシューティカルズ・インコーポレーテッド Ｃ型肝炎ウイルス感染に関連する疾患または状態の酵素的核酸治療
WO2000000638A2 (en) * 1998-06-26 2000-01-06 Akzo Nobel N.V. Tagging of rna amplicons generated by transcription-based amplification
US6300075B1 (en) * 1999-02-03 2001-10-09 Ortho-Clinical Diagnostics, Inc Enhancement of the specificity of nucleic acid amplification by carrier nucleic acid
US6638714B1 (en) * 1999-02-03 2003-10-28 Ortho-Clinical Diagnostics, Inc. Oligonucleotide primers for efficient detection of hepatitis C virus (HCV) and methods of use thereof
DE60034884T2 (de) * 1999-06-04 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
US6271004B1 (en) * 1999-06-25 2001-08-07 Display Systems Biotech A/S Method for improved reverse transcription at high temperatures
EP1233976A4 (en) * 1999-11-17 2003-06-11 Jiuping Ji SIMULTANEOUS DETECTION OF HBV, HCV AND HIV IN PLASMA SAMPLES WITH THE AID OF A MULTIPLEX FIXING TEST
AU2001254670A1 (en) * 2000-03-02 2001-09-12 Akzo Nobel N.V. Detection of hepatitis b virus rna
CA2442092A1 (en) * 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
WO2003016572A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Oligonucleotide therapeutics for treating hepatitis c virus infections
US6783940B2 (en) 2001-10-31 2004-08-31 Applera Corporation Method of reducing non-specific amplification in PCR
US6750009B2 (en) * 2002-01-29 2004-06-15 Apath, Llc Multiple viral replicon culture systems
WO2003100014A2 (en) * 2002-05-24 2003-12-04 Smithkline Beecham Corporation Method for quantitating negative strand rna synthesis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837463A (en) * 1919-10-17 1998-11-17 Rational Drug Design Laboratories Nucleic acid of C type hepatitis virus derivation and process for detection virus using said nucleic acid
US5032511A (en) * 1987-03-31 1991-07-16 Mitsubishi Kasei Corporation DNA fragments coding for antigens specific to non-A non-B hepatitis, expression vectors containing said DNA fragments, transformants and process for producing said antigens
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5863719A (en) * 1987-11-18 1999-01-26 Chiron Corporation Methods for detecting hepatitis C virus using polynucleotides specific for same
US6074816A (en) * 1987-11-18 2000-06-13 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6297003B1 (en) * 1995-08-29 2001-10-02 Washington University Methods for the detection of a novel hepatitis C virus (HCV) terminal 3′ noncoding region

Also Published As

Publication number Publication date
EP2042612A3 (en) 2009-06-17
WO2005071117A3 (en) 2006-04-20
JP2007518424A (ja) 2007-07-12
US7364854B2 (en) 2008-04-29
DE602005025424D1 (de) 2011-01-27
EP2042612A2 (en) 2009-04-01
JP2007518425A (ja) 2007-07-12
US20060019266A1 (en) 2006-01-26
US7670779B2 (en) 2010-03-02
US20080248480A1 (en) 2008-10-09
EP1721015A2 (en) 2006-11-15
EP2042612B1 (en) 2010-12-15
DE602005011754D1 (de) 2009-01-29
WO2005070027A8 (en) 2006-07-27
WO2005070027A3 (en) 2006-04-06
EP1706512A2 (en) 2006-10-04
DE602005023586D1 (de) 2010-10-28
ATE417938T1 (de) 2009-01-15
ATE491810T1 (de) 2011-01-15
JP4866248B2 (ja) 2012-02-01
ATE481507T1 (de) 2010-10-15
WO2005071117A2 (en) 2005-08-04
WO2005070027A2 (en) 2005-08-04
EP1706512B1 (en) 2008-12-17
EP1721015B1 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
US7115374B2 (en) Compositions and methods for detecting West Nile virus
EP4202064A1 (en) Kit and method for isothermal rapid detection of sars-cov-2 virus nucleic acid
JP6659206B2 (ja) 増幅中の高分子量生成物を防止する方法
JP5272268B2 (ja) 遮断プライマーを使用する改善された多重核酸増幅
WO2008090340A2 (en) Nucleic acid amplification and testing
EP1849304A2 (en) Method and apparatus for real-time frame encoding
US20070281295A1 (en) Detection of human papillomavirus E6 mRNA
US20060003343A1 (en) Primer and probe design for efficient amplification and detection of HCV 3' non-translating region
JP2019531747A (ja) Ｃ型肝炎ウイルスを検出または定量するための組成物および方法
US20250154612A1 (en) Compositions and Methods for Detecting or Quantifying Hepatitis B Virus
US7927840B2 (en) Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
WO2021221109A1 (ja) Ｒｎａウイルスの検出方法
US8008045B2 (en) Primers for isothermal amplification of hepatitis C virus
CN110892082A (zh) 丙型肝炎病毒(hcv)的测定
CN101415843B (zh) 通过扩增和检测复制酶序列分析sars冠状病毒
CN121109659A (zh) 一种针对呼吸道病原体rna的多重tma-crispr试剂盒及其应用
JP2022508954A (ja) ヒトポリオーマウイルスｂｋウイルスを増幅、検出または定量化するための組成物および方法
WO2020117769A1 (en) Hcv detection
JP2006271324A (ja) 核酸検出法
AU2008200221A1 (en) Compositions and methods for detecting west nile virus

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOMERIEUX, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, HWA-TANG THOMAS;WASHBURN, BRIAN;PUROHIT, PRAKASH;AND OTHERS;REEL/FRAME:016973/0292;SIGNING DATES FROM 20050721 TO 20050819

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION